Clinical trials
Full profile accessFollow clinical development from trial design and recruitment through results.
- Trial phase
- Status
- Readouts
Company intelligence / Profile preview
M8 Pharmaceuticals has a broad commercial-stage portfolio in Latin America with exclusive licensing agreements for innovative and established medicines. Recent deals include rights to Qelbree® (viloxazine XR) for CNS indications and Voraxaze® (glucarpidase) for cancer patients. The company also recently partnered with LG Chem to bring novel treatments for type 2 diabetes and osteoarthritis to the region. Its pipeline covers CNS disorders; cardiometabolic; respiratory; gastroenterology; oncology/hematology; immunology; and rare diseases.
Beyond the preview
Explore clinical development, deal activity, and the competitive landscape with Gosset’s full data platform.
Follow clinical development from trial design and recruitment through results.
Explore licensing agreements, acquisitions, and the assets behind each deal.
Trace financing activity and the investors behind a company’s development.
Compare peer pipelines by target, modality, and therapeutic area.
Explore technology platforms and the patent landscape around relevant assets.
Connect company news and source material to the questions you’re investigating.
See how Gosset can support your research on M8 Pharmaceuticals.